Henry Meds Review 2026: Bundled GLP-1 Telehealth With No Membership Fee

What Is Henry Meds?

Henry Meds is a US telehealth company that provides compounded GLP-1 receptor agonists — semaglutide and tirzepatide — alongside other prescription treatments including testosterone replacement therapy, hair loss, and primary care. Its GLP-1 program is the flagship offering: patients complete an online intake, consult with a licensed provider, receive a compounded prescription, and have medication shipped directly to their door, all for a single flat monthly fee.

Unlike platforms that charge a membership fee on top of medication costs, Henry Meds bundles everything — provider visits, compounding pharmacy fulfillment, supplies such as syringes, and shipping — into one all-in price. The platform serves patients in all 50 states and routes prescriptions through a network of 503A compounding pharmacies, which are patient-specific pharmacies operating under a different regulatory framework than the 503B outsourcing facilities that have drawn FDA scrutiny in 2025 and 2026.

How Henry Meds Works

The onboarding process is fully asynchronous to start. You complete a health questionnaire covering your medical history, current medications, weight history, and treatment goals. A licensed provider — typically a physician or nurse practitioner — reviews your intake and, if clinically appropriate, issues a compounded GLP-1 prescription. Henry Meds then coordinates shipment directly from a compounding pharmacy to your address, with ongoing provider access included for dose adjustments and check-ins.

• Complete an online health intake form covering medical history, BMI, and goals
• Provider reviews intake and conducts a telehealth consultation
• Prescription written and sent to Henry Meds' 503A compounding pharmacy network
• Medication ships directly to your door — syringes and supplies included for injections
• Ongoing provider access for dose titration and follow-up questions
• Cancel anytime with no cancellation fee

Medications and Formats

Henry Meds offers compounded semaglutide and compounded tirzepatide in two formats each: a weekly subcutaneous injection and an oral formulation. This four-way menu is noteworthy for women in perimenopause and menopause, who frequently encounter injection anxiety or prefer to manage as few new self-administered procedures as possible during a period already dense with symptom management. The oral options provide the same active GLP-1 mechanism without needles, though absorption characteristics differ from injectables.

• Compounded semaglutide oral — $249/mo, needle-free weekly administration
• Compounded semaglutide injection — $297/mo, standard weekly subcutaneous shot with supplies included
• Compounded tirzepatide oral — $349/mo, needle-free dual GIP/GLP-1 agonist
• Compounded tirzepatide injection — $449/mo, injectable form of the dual-mechanism agonist

Tirzepatide's dual mechanism — activating both GLP-1 and GIP receptors — is associated with greater average weight loss in clinical trials compared to semaglutide alone. For menopausal women dealing with accelerated visceral fat accumulation and declining insulin sensitivity, the additional GIP pathway may provide a metabolic edge. Henry Meds offers both, letting the prescribing provider and patient choose the best fit based on health history and tolerance.

Pricing: What You Actually Pay

Henry Meds uses an all-in pricing model with no separate membership or enrollment fee. What you see is what you pay: one monthly charge that covers the provider consultation, the compounded medication, supplies, and shipping. Prices do not escalate as your dose increases — a meaningful advantage for patients who may spend months at higher maintenance doses.

• Compounded semaglutide oral: $249/mo — all-in
• Compounded semaglutide injection: $297/mo — all-in, supplies and shipping included
• Compounded tirzepatide oral: $349/mo — all-in
• Compounded tirzepatide injection: $449/mo — all-in, supplies and shipping included
• No insurance accepted for compounded medications
• HSA and FSA cards are generally accepted — confirm eligibility with your plan administrator

Annual cost estimates range from approximately $2,988 per year for compounded semaglutide oral up to $5,388 per year for compounded tirzepatide injection. For comparison, branded Wegovy without insurance commonly retails above $1,300 per month, and Zepbound lists around $550–$650 per month at pharmacy retail. Henry Meds' all-in compounded pricing is a fraction of branded cost, though patients should be aware of the regulatory landscape for compounded GLP-1s going into the second half of 2026.

The 503A Pharmacy Model: What It Means for Patients

Henry Meds' prescriptions are filled by 503A compounding pharmacies — state-licensed pharmacies that compound medications for individual patients based on a specific prescription. This is different from 503B outsourcing facilities, which compound in large batches without patient-specific prescriptions and have been the primary target of FDA enforcement actions in 2025 and 2026. Because Henry Meds operates within the 503A framework, its compounding pharmacies are not directly subject to the FDA's proposed April 2026 rule that would remove semaglutide and tirzepatide from the 503B bulk compounding list.

That said, the regulatory environment for compounded GLP-1s continues to evolve. The FDA's position on 503A compounding of copies of commercially available drugs remains nuanced and subject to change. Patients should ask their Henry Meds provider which pharmacy is filling their prescription and confirm that pharmacy holds current state licensure.

Who Henry Meds Is Best For

Henry Meds is a strong option for patients who want transparent, bundled GLP-1 pricing without the overhead of a separate membership fee. The all-in model is especially appealing for cost-conscious patients who want to understand their exact monthly outlay before enrolling. The oral medication formats make it accessible to needle-averse patients, and the tirzepatide options serve those who want the strongest efficacy evidence currently available.

• Adults with a BMI of 27 or higher looking for a straightforward GLP-1 telehealth entry point
• Perimenopausal and menopausal women managing weight changes alongside hormonal shifts
• Patients who want oral GLP-1 options without weekly injections
• Budget-focused patients who prefer one all-in price with no membership fee surprises
• People in rural or underserved areas who need nationwide telehealth coverage
• Patients who are comfortable without bundled lab monitoring

Henry Meds is a weaker fit for patients who want insurance billing, bundled lab work, or access to branded GLP-1 medications such as Wegovy or Zepbound. It is also not the right choice for patients who want obesity medicine specialists with formal board certification — Henry Meds uses licensed providers but does not specifically advertise ABOM certification as a network requirement.

Verdict

Henry Meds delivers a clean, bundled GLP-1 telehealth experience with four medication options, nationwide reach, and pricing that doesn't play games. The all-in monthly fee — no membership add-on, no dose escalation charge — makes it one of the most transparent pricing models in the telehealth GLP-1 market. For perimenopausal and menopausal women who want an oral option or who are price-sensitive, the entry points at $249/mo for oral semaglutide and $349/mo for oral tirzepatide are genuinely competitive.

The key unknown going into the second half of 2026 is the regulatory trajectory for compounded GLP-1s. Henry Meds' 503A model offers some insulation from the FDA's proposed 503B exclusion, but the broader legal environment is not settled. Patients should enroll with an understanding that the compounded medication landscape may shift, and should verify their dispensing pharmacy's current licensure when they start.